Immitra Bio Secures €2.58 Million in Pre-Seed Round
Immitra Bio, a Zürich-based company working on scalable in-vivo genomic medicine for blood disorders, has successfully raised €2.58 million in a pre-seed funding round. This round was led by Backbone Ventures, with participation from several other investors.
Investors and Funding Details
The pre-seed funding round saw significant contributions from a range of investors, including OCCIDENT, Another VC, Kickfund, Venture Kick, Zürcher Kantonalbank, FONGIT, and the ETH Foundation. Backbone Ventures took the lead in this round, which also included €161.8k in non-dilutive funding. This means that Immitra Bio retained full ownership over this portion of the funds.
Leadership and Vision
The company was co-founded by Amir Taheri-Ghahfarokhi, who serves as Chief Scientific Officer, and Jan Nelis, the CEO. Nelis stated, "At Immitra Bio, we are advancing a fundamentally new approach to gene editing therapies and are proud to be backed by a syndicate of early-stage and life science specialist investors."
Strategic Use of Funds
The newly secured funds are earmarked for accelerating the development of Immitra Bio's gene-editing platform. The company aims to make genetic treatments more scalable and commercially viable, potentially generating numerous therapeutic assets.
Future Outlook
With this financial backing, Immitra Bio is set to establish itself as a leader in the field of in-vivo gene editing. The company aims to enhance the accessibility of gene editing therapies, making them a viable option for patients suffering from blood disorders.
This investment marks a significant step in advancing Immitra Bio’s mission to transform the landscape of genomic medicine.